` CRBP (Corbus Pharmaceuticals Holdings Inc) vs S&P 500 Comparison - Alpha Spread

CRBP
vs
S&P 500

Over the past 12 months, CRBP has underperformed S&P 500, delivering a return of -85% compared to the S&P 500's +13% growth.

Stocks Performance
CRBP vs S&P 500

Loading
CRBP
S&P 500
Add Stock

Performance Gap
CRBP vs S&P 500

Loading
CRBP
S&P 500
Difference
www.alphaspread.com

Performance By Year
CRBP vs S&P 500

Loading
CRBP
S&P 500
Add Stock

Competitors Performance
Corbus Pharmaceuticals Holdings Inc vs Peers

S&P 500
CRBP
ABBV
CYTH
AMGN
GILD
Add Stock

Corbus Pharmaceuticals Holdings Inc
Glance View

Market Cap
105m USD
Industry
Biotechnology

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company is headquartered in Norwood, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2014-10-24. The Company’s pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. The firm pipeline includes Anti-integrin monoclonal antibodies (mAbs), Cannabinoid receptor type 1 (CB1) and Lenabasum. The mAbs is for the treatment of cancer and fibrosis that inhibit the activation of Transforming growth factor β (TGFβ). Its CRB-601 is an anti-αvβ8 mAb being developed as a potential treatment for solid tumors in combination with existing therapies, including checkpoint inhibitors. Cannabinoid receptor type 1 (CB1) is an inverse agonist designed to treat obesity and related metabolic diseases. Lenabasum is a novel, synthetic, oral molecule that selectively activates cannabinoid receptor type 2 (CB2).

CRBP Intrinsic Value
Not Available
Back to Top